Research suggests that the time of day when certain treatments—such as cancer therapies or vaccines—are given can influence their effectiveness. Scientists are examining how the body’s internal clock, or circadian rhythm, might be the key to unlocking better patient outcomes.

Mdxhealth has unveiled new findings from Oxford’s ProMPT Study, which show that the Genomic Prostate Score (GPS) test can predict adverse outcomes for prostate cancer patients. Presented at EAU 2026, this research highlights the test’s broad relevance across multiple treatment approaches.

A groundbreaking community laboratory in Wilmington, Delaware, is now growing patient-derived “mini tumors” to guide future cancer treatments. ChristianaCare’s new organoid core—described as the first-of-its-kind—could help pave the way for more precise therapies.

In a landmark move, the Chan Zuckerberg Initiative and the Innovative Genomics Institute have announced a new center dedicated to bringing personalized CRISPR cures to children with rare genetic diseases.